Purpose: Sunitinib is a multitargeted receptor tyrosine kinase inhibitor. We conducted a two-stage phase II study to evaluate the objective response rate of oral sunitinib in recurrent epithelial ovarian cancer.
introduction
Ovarian cancer is the leading cause of gynecologic cancer death in North America. In 2008, an estimated 22 000 and 2500 women were diagnosed with this disease in the United States and Canada, respectively; at least 70% would be expected to die of their disease [1, 2] . The standard front-line treatment of ovarian cancer includes debulking surgery followed by combination chemotherapy that includes a platinum drug and a taxane [3] . Patients with primary peritoneal carcinomatosis (PPC) and advanced fallopian tube cancers are managed in a comparable manner to ovarian cancer, and such patients are commonly included in ovarian cancer clinical trials.
Despite aggressive primary management, the majority of ovarian cancer patients will relapse and die of their disease.
Systemic chemotherapy in the relapsed or refractory setting, while having been shown to prolong survival, is not curative [4] . Among the most important determinants of survival in recurrent ovarian cancer is the platinum-free interval (PFI), the time from completion of front-line platinum to first evidence of recurrence. Patients with a PFI of at least 6 months have a higher likelihood of response to platinum and other chemotherapy drugs and an increased survival [5, 6] . Importantly, clinicians must balance chemotherapy toxic effects with quality of life considerations when considering treatment of relapsed or refractory disease. Clearly, novel and more promising systemic treatment options are required. Targeted molecular-based therapies that appear to have favorable toxicity profiles need to be studied in ovarian cancer.
Among the many growth stimuli exploited by malignancies, which accordingly may provide targets for novel therapeutics, are the components of the complex process of angiogenesis.
Aberrant components of angiogenic pathways are now known to play a major role in malignant progression and metastasis, wherein neoangiogenic processes appears to be triggered during the multiple stages of tumorigenesis [7] . Indicators of enhanced angiogenesis in malignancy, such as elevated circulating blood levels of vascular endothelial growth factor (VEGF) and tissue microvessel density, have been correlated with metastasis and survival in most malignancies, including ovarian cancer [8] . Important among the many angiogenesis pathway components are cell surface VEGF receptors and platelet-derived growth factor (PDGF) receptors. PDGF and its receptor pathway have been implicated in preclinical models of ovarian cancer progression [9] . Similarly, the VEGF signaling pathway appears to contribute to growth and progression in ‡80% of all ovarian cancers. In one study, Yamamoto et al. [10] described a strong correlation between VEGF immunohistochemical staining of tumor samples and patient survival and between tumor fluid levels of VEGF and tumor burden. Hence, it is rational to study therapies targeted to these elements of the angiogenesis signaling pathways in this disease. The first clinical evidence of angiogenesis inhibition has come from the early studies of bevacizumab, an anti-VEGF monoclonal antibody; three trials of this agent in recurrent ovarian cancer (as single agent or in combination) have been reported and show antitumor activity [11] [12] [13] .
Sunitinib (SU11248) is a novel multitargeted small molecule receptor tyrosine kinase (RTK) inhibitor. Potent activity was demonstrated in preclinical models against a number of RTK targets, including VEGF and PDGF receptors (VEGFR-1, VEGFR-2 and VEGFR-3 and PDGFR-a and PDGFR-b). In subsequent murine xenograft models, growth inhibition against a variety of solid cancers was reported; daily dosing was sufficient to produce a persistent inhibition of VEGF-RTK and PDGF-RTK phosphorylation [14] . When sunitinib was combined with a variety of single chemotherapy agents using in vivo models, synergistic activity was demonstrated [15, 16] .
In the phase I studies in humans, tumor regression was seen in some patients and recommended doses in both intermittent and daily oral sunitinib dosing schedules were established [17, 18] . Phase II recommended doses/schedules were 50 mg p.o. daily for 4 of 6 weeks and 37.5 mg p.o. daily continuously. The most frequent adverse events (AEs) in phase I studies were constitutional (fatigue/asthenia), gastrointestinal (nausea, vomiting and diarrhea), hematologic (neutropenia and thrombocytopenia) and hypertension.
In subsequent phase II and phase III clinical trials of patients with previously treated gastrointestinal stromal tumors and renal cell cancers, impressive response and stable disease (SD) rates were reported using single-agent sunitinib, with a modest toxicity profile [19, 20] . Phase II studies in previously treated metastatic breast and non-small-cell lung cancer reported modest objective response rates with acceptable toxicity [21, 22] , and phase II studies are ongoing with other solid tumors including breast and prostate cancers.
Because of the data suggesting PDGF and VEGFR are important biological targets for therapy in ovarian cancer, NCIC Clinical Trials Group undertook a phase II trial of oral sunitinib in patients with recurrent epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer.
patients and methods

patients and eligibility criteria
Patients were eligible if they had histologically confirmed epithelial ovarian, primary fallopian or primary peritoneal cancer, with advanced or recurrent disease considered incurable by standard therapies. At least one site of measurable disease as defined by RECIST [23] was required; CA125 elevation alone was insufficient for enrollment. Patients must have received at least one but no more than two prior chemotherapy regimens, one of which had to include platinum chemotherapy. Platinum-sensitive (PFI >6 months) and platinum-refractory or -resistant patients were eligible. The minimum age was 18 years with a performance status of Eastern Cooperative Oncology Group zero or one and life expectancy at least 12 weeks at baseline.
Prior hormonal and radiation therapy, and previous major surgery if at least 28 days before registration, were allowed. Adequate organ function was required based on the following laboratory parameters: neutrophil count ‡1.5 · 10 9 /l, platelets ‡100 · 10 9 /l, bilirubin £ upper limit of normal (ULN), aspartate aminotransferase and alanine aminotransferase £ 2.5 · ULN, serum creatinine £ ULN or creatinine clearance ‡60 ml/min measured directly by 24-h urine sampling or calculated by Cockcroft Formula and calcium £3 mmol/l. Baseline investigations included CA125, thyroid-stimulating hormone (TSH) and T4, electrocardiogram to determine QTc plus left cardiac ventricular function assessed by multigated acquisition scan if clinically indicated. Before registration, each patient had to have signed an informed consent document, which was approved by the local research ethics board (REB).
Patients were excluded if there was a history of the following: other malignancies (except adequately treated nonmelanoma skin cancer and curatively treated in situ cancer); known brain metastases; prior treatment with any other antiangiogenic agent or multitargeted tyrosine kinase inhibitor; inadequately controlled hypertension or hypothyroid state unless medically controlled; symptomatic or NYHA class III or IV heart failure; QTc prolongation; myocardial infarction, cardiac arrhythmia, stable/ unstable angina, coronary or peripheral artery bypass graft or stenting or pulmonary embolism within 12 months and requirement for use of therapeutic coumarin-derivative anticoagulants such as warfarin. The study was not open to pregnant or lactating women or women of childbearing potential who did not agree to use adequate contraception. Known HIVpositive patients on combination antiretroviral therapy were ineligible because of the potential for pharmacokinetic interactions.
Because sunitinib is metabolized primarily by the CYP3A4 liver enzyme pathway, patients were prohibited from using potent inhibitors or inducers of CYP3A4 for at least a week before and while on therapy.
treatment plan, response evaluation and patient monitoring REB approval of the protocol was required in all participating centers before the trial could be opened for accrual. Sunitinib [supplied by the Cancer Therapy Evaluation program, National Cancer Institute (NCI), Bethesda, MD] was given initially at a starting dose of 50 mg once daily for 4 of every 6-week cycle. As described in the 'Results' section, due to the observation of apparent VEGF-rebound related fluid collections occurring in some patients, the starting dose/schedule was modified for the second stage of accrual to 37.5 mg p.o. daily continuously on a 4-week cycle. Doses were to be reduced for grade 3 or 4 AEs, asymptomatic cardiac events and persistent hypertension not responsive to medication. Drug was to be discontinued for most grade 4 events, toxicity requiring more than two dose reductions and symptomatic cardiac events. Treatment was to continue until one of the following: completion of therapy as per protocol, development of intercurrent illness, unacceptable toxicity, clinical or radiographic disease progression or patient decision to withdraw. Complete and partial responders were offered to continue therapy until progression original article Annals of Oncology or for two cycles after response criteria were met. SD patients were to continue for a maximum of six cycles.
While on therapy, patients were evaluated day 1 each cycle for vital signs, clinical tumor measurements, urine analysis, CA125 levels, AEs, hematology and biochemistry. Thyroid function was assessed every other cycle and blood pressure, which was monitored weekly for the first cycle of therapy, and was then assessed every 2 weeks thereafter. Management of sunitinibinduced hypertension was outlined in the protocol. Imaging was carried out at the end of every 6-week cycle in stage 1 of accrual and at the end of every two 4-week cycles (every 8 weeks) in stage 2 of accrual.
Objective tumor response was defined using RECIST [23] criteria and CA125 response (a secondary end point) using Gynecologic Cancer Intergroup (GCIG) criteria [24] .
study end points and statistical considerations
The primary end point of this trial was objective response rate. The trial used a two-stage design [25] to test the null hypothesis that response rate of sunitinib is 5% versus the alternative hypothesis that the response rate is 20%. In stage 1 of accrual, 15 response-assessable patients were to be entered. If no responses were seen, the study would close and the agent declared uninteresting. If one or more responses were documented, an additional 10 patients would be accrued to the stage 2 cohort. At the end of study accrual, the agent would be declared interesting if three or more responses were observed in the final sample of 25 patients accrued. This design has an alpha of 0.12 and a power of 0.89 (b 0.11) when the true response rate is 20%. 
patient entry
Of the 31 patients enrolled, 30 were eligible (one ineligible due to uncontrolled hypothyroidism at entry). All were assessable for nonhematologic toxicity, 29 for hematological toxicity and 28 for response. Of the 31 patients entered, 17 were treated on the 50 mg intermittent dose cycle in stage 1 of accrual and 14 at the 37.5 mg continuous dose schedule in stage 2 of accrual. Patient characteristics are listed in Table 1 . Three patients had PPC and the remainder ovarian cancer. Most patients had serous histology (67%), were platinum sensitive (73%) and had two lines of prior chemotherapy (60%). For the 22 platinumsensitive patients, median PFI was 11 months (range 6-24).
treatment delivery
Ninety per cent of planned dose intensity was achieved in 63% and 57% of patients at the initial doses of 50 and 37.5 mg, respectively. Patients on the high-dose intermittent schedule received a median of three (range 1-6) cycles and those on the continuous dose schedule received a median of four cycles (range 1-10). On both dose schedules, the most common reasons for missed doses were mucositis and hand-foot syndrome. By comparison, doses at 50 mg were commonly missed for nausea versus granulocytopenia, fatigue, anorexia and hypertension at 37.5 mg.
adverse effects
Thirty patients were assessable for toxicity (Table 2 ). Significant hematologic and nonhematological adverse effects were uncommon. The most common AEs assessed as related to sunitinib included fatigue, mucositis, nausea, taste alteration, hand-foot syndrome, diarrhea, hypertension and pain (abdominal). Comparing the two dose schedules, incidence of hypertension (56% versus 29%, respectively), mucositis (63% versus 50%, respectively) and skin discoloration (38% versus 14%, respectively) were higher at the 50 mg dose, while diarrhea (50% versus 31%, respectively), fatigue (86% versus 69%, respectively) and anorexia (50% versus 25%, respectively) were higher at the 37.5 mg dose. Hematologic toxic effects were not different between the two dose schedules. In patients with normal baseline biochemistries, all events were grade 1, with the exception of one grade 3 hypokalemia (recovered within 1 day), one grade 3 creatinine and two grade 2 hypoalbuminemia. TSH elevations were documented in 13 patients, 2 of whom required initiation of thyroid replacement therapy on study. There were 21 serious AE (NCI Adverse Event Expedited Reporting System) reports in 14 patients, 3 of which met Health Canada criteria for expedited reporting.
There was no incidence of gastrointestinal perforation.
Although not strictly an AE, we did note fluid accumulation (ascites or effusion), often considered evidence of disease progression, appearing at the end of cycle assessments in some patients on the intermittent schedule. This was provocative given that in three such cases, effusions were reported in the face of other evidence of disease response (see Table 3 ). Since ovarian cancer is a tumor type that may have fluid accumulation induced by VEGF mechanisms, it was speculated that a rebound effect of increased VEGF levels during the 2-week off drug holiday could have been responsible for the fluid accumulation, rather than disease progression. When the protocol criteria for continuing to stage 2 of accrual were met (i.e. at least one confirmed response was seen), it was decided to amend the schedule of sunitinib to a continuous dosing schedule to see if this would have an impact on this phenomenon. Thus, the protocol was amended to 37.5 mg sunitinib p.o. daily continuously for stage 2 of accrual as noted in the 'Patients and Methods' section.
tumor and CA125 response
All patients have gone off study: tumor progression was the most common reason for discontinuing therapy (18 patients) followed by symptomatic progression (4), AEs (3), completion of therapy (3) and other (3). Twenty-eight patients are assessable for objective tumor and CA125 responses (Table 4) . One partial response (PR) (duration 5 months) and three CA125 responses were confirmed, all in the 50 mg intermittent dose cohort. The response rate for all eligible patients was therefore 3.3% (95% confidence interval 0.1% to 17.2%). Overall, 16 patients had SD, 11 at the 50 mg and 5 at 37.5 mg dose, with a median overall duration of 6.4 months. Overall median progression-free survival (PFS) was 4.1 months (Figure 1) . All tumor and CA125 responses were seen in patients who were at least 6 months since their last platinum treatment, while four of eight patients who had platinum treatment interval <6 months achieved SD (median 5.3 months).
We also analyzed maximal tumor regression and CA125 fall in waterfall plot format (Figures 2 and 3) . The waterfall plot of maximal tumor regression demonstrated five patients on the 50 mg intermittent dose schedule who achieved >30% decrease in measurable disease, only one a confirmed RECIST PR. In the 25 patients who had baseline CA125 elevated more than twice normal, a fall in CA125 of >50% was seen in 6 patients (46%) on the intermittent and 3 (25%) on the continuous dose schedules. Only three (all on intermittent high-dose schedule) met GCIG criteria for confirmation of CA125 response.
discussion
Sunitinib as a single agent was generally well tolerated in patients with recurrent ovarian cancer and PPC but demonstrated modest activity. However, despite only one objective response, the PFS of our patients (4.1 months) is in line with published results of other trials of single-agent antiangiogenic agents. In a trial of single-agent monoclonal antibody bevacizumab for patients with platinum-resistant disease, Cannistra et al. [26] reported a PR rate of 16% and PFS of 4.4 months, although there was a 16% rate of gastrointestinal perforation in this heavily pretreated population and the trial was therefore terminated early. Burger et al. [11] studied singleagent bevacizumab in platinum-sensitive disease and observed a 21% response rate and PFS of 4.7 months; gastrointestinal perforation was not a significant toxicity. The oral agent cediranib, also a VEGF-RTK inhibitor, was tested in platinumsensitive and -resistant disease, with reported objective responses and a thymidine triphosphate of 4.1 months [27] . Platinum-refractory disease is particularly challenging and systemic therapy is associated with very modest responses or symptomatic benefit. In our trial, sunitinib did not induce objective response in the eight such patients enrolled. However, angiogenesis does appear to be an appropriate target in this disease. Bevacizumab and cediranib studies have reported objective responses in this patient subset.
It is noteworthy that of the five patients on the 50 mg intermittent dose schedule who achieved >30% decrease in measurable disease (see Figure 2 , waterfall plot of maximal tumor regression), two did not contribute to response rate by RECIST criteria because they were removed from study for 'progressive disease' due to development of increased/new [28] . Studies of antiangiogenesis agents in oncology have started to identify a potential serum VEGF rebound that occurs when the agent is discontinued, which may have clinical relevance [29] . If an effusion is asymptomatic, it is possible that removal of patients from study for apparent progression may be premature if the fluid accumulation is related to VEGF rebound. We can only speculate if continuation of treatment of such patients in the current trial would have resulted in a higher observed response rate.
With increasing interest in the study of targeted antiangiogenesis agents in ovarian cancer, safety and tolerability must be taken into account. Sunitinib, similar to other agents in its class, is associated with hypertension, fatigue and gastrointestinal symptoms. In our study, there was one case of grade 3 hypertension but was manageable and allowed the patient continued therapy. Grade 3-4 toxic effects were uncommon; however, we found that some patients discontinued therapy for an accumulation of grade 1 and grade 2 toxic effects. For example, one patient discontinued therapy after experiencing grade 2 anorexia and hypertension and grade 1 blurred vision, fatigue and pain due to headache. These low grade but persistent toxic effects clearly impact quality of life and ability to continue therapy. The evidence of modest efficacy in our trial indicates that sunitinib may merit further study in advanced ovarian cancer, but dose and schedule may be important parameters that require further evaluation in any future study. A randomized phase II trial of the two schedules used in our study has recently been completed in Germany and may shed light on this question.
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